鲍曼不动杆菌临床分离株对舒巴坦联合新型β-内酰胺酶抑制剂 ETX2514 自发耐药的频率和机制。
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.
机构信息
Entasis Therapeutics, Waltham, Massachusetts, USA
Entasis Therapeutics, Waltham, Massachusetts, USA.
出版信息
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01576-17. Print 2018 Feb.
Abstract
The novel diazabicyclooctenone ETX2514 is a potent, broad-spectrum serine β-lactamase inhibitor that restores sulbactam activity against resistant The frequency of spontaneous resistance to sulbactam-ETX2514 in clinical isolates was found to be 7.6 × 10 to <9.0 × 10 at 4× MIC and mapped to residues near the active site of penicillin binding protein 3 (PBP3). Purified mutant PBP3 proteins demonstrated reduced affinity for sulbactam. In a sulbactam-sensitive isolate, resistance also mapped to stringent response genes associated with resistance to PBP2 inhibitors, suggesting that in addition to β-lactamase inhibition, ETX2514 may enhance sulbactam activity in via inhibition of PBP2.
摘要
新型二氮杂二环辛酮 ETX2514 是一种强效、广谱的丝氨酸 β-内酰胺酶抑制剂，可恢复舒巴坦对耐药的活性。在临床分离株中，舒巴坦-ETX2514 自发耐药的频率在 4×MIC 时为 7.6×10 至 <9.0×10，定位于青霉素结合蛋白 3（PBP3）的活性部位附近的残基。纯化的突变 PBP3 蛋白显示对舒巴坦的亲和力降低。在舒巴坦敏感的分离株中，耐药性也定位于与 PBP2 抑制剂耐药相关的严格反应基因，表明除了β-内酰胺酶抑制作用外，ETX2514 还可能通过抑制 PBP2 来增强舒巴坦在 中的活性。
相似文献
1
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii.
Antimicrob Agents Chemother. 2018 Jan 25;62(2). doi: 10.1128/AAC.01576-17. Print 2018 Feb.
2
Targeting Multidrug-Resistant spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent.
mBio. 2019 Mar 12;10(2):e00159-19. doi: 10.1128/mBio.00159-19.
3
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.
4
Potent β-Lactam Enhancer Activity of Zidebactam and WCK 5153 against Acinetobacter baumannii, Including Carbapenemase-Producing Clinical Isolates.
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01238-17. Print 2017 Nov.
5
Activity of Sulbactam-Durlobactam against Acinetobacter baumannii- Complex Isolates Collected Globally in 2016 and 2017.
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.02534-19.
6
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting .
Future Microbiol. 2024;19(7):563-576. doi: 10.2217/fmb-2023-0248. Epub 2024 Mar 1.
7
Molecular drivers of resistance to sulbactam-durlobactam in contemporary clinical isolates of .
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0066523. doi: 10.1128/aac.00665-23. Epub 2023 Oct 16.
8
Durlobactam, a Broad-Spectrum Serine β-lactamase Inhibitor, Restores Sulbactam Activity Against Acinetobacter Species.
Clin Infect Dis. 2023 May 1;76(Suppl 2):S194-S201. doi: 10.1093/cid/ciad095.
9
OXA-23 Is a Prevalent Mechanism Contributing to Sulbactam Resistance in Diverse Acinetobacter baumannii Clinical Strains.
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01676-18. Print 2019 Jan.
10
In vitro antibacterial activity of sulbactam-durlobactam in combination with other antimicrobial agents against Acinetobacter baumannii-calcoaceticus complex.
Diagn Microbiol Infect Dis. 2024 Jul;109(3):116344. doi: 10.1016/j.diagmicrobio.2024.116344. Epub 2024 May 9.
引用本文的文献
1
treatment strategies: a review of therapeutic challenges and considerations.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0106324. doi: 10.1128/aac.01063-24. Epub 2025 Jul 9.
2
A Comprehensive Overview of Antibacterial Agents for Combating Multidrug-Resistant Bacteria: The Current Landscape, Development, Future Opportunities, and Challenges.
Antibiotics (Basel). 2025 Feb 21;14(3):221. doi: 10.3390/antibiotics14030221.
3
Sulbactam-Durlobactam: A Novel Antibiotic Combination for the Treatment of -Calcoaceticus Complex (ABC) Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia.
Can J Infect Dis Med Microbiol. 2025 Jan 29;2025:2001136. doi: 10.1155/cjid/2001136. eCollection 2025.
4
Population pharmacokinetic analyses for sulbactam-durlobactam using Phase 1, 2, and 3 data.
Antimicrob Agents Chemother. 2025 Jan 31;69(1):e0048524. doi: 10.1128/aac.00485-24. Epub 2024 Nov 21.
5
New Agents Are Coming, and So Is the Resistance.
Antibiotics (Basel). 2024 Jul 13;13(7):648. doi: 10.3390/antibiotics13070648.
6
Optimizing Treatment for Carbapenem-Resistant Complex Infections: A Review of Current Evidence.
Infect Chemother. 2024 Jun;56(2):171-187. doi: 10.3947/ic.2024.0055.
7
Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria.
Antibiotics (Basel). 2024 Mar 15;13(3):260. doi: 10.3390/antibiotics13030260.
8
Sulbactam-durlobactam: a β-lactam/β-lactamase inhibitor combination targeting .
Future Microbiol. 2024;19(7):563-576. doi: 10.2217/fmb-2023-0248. Epub 2024 Mar 1.
9
activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant collected in U.S. hospitals.
Antimicrob Agents Chemother. 2024 Mar 6;68(3):e0125823. doi: 10.1128/aac.01258-23. Epub 2024 Jan 30.
10
Sulbactam-Durlobactam, A Novel Drug for the Treatment of Multidrug Resistant Infections - A Systematic Review.
Infect Disord Drug Targets. 2024;24(6):e220124225835. doi: 10.2174/0118715265276432231217192054.
本文引用的文献
1
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii.
Nat Microbiol. 2017 Jun 30;2:17104. doi: 10.1038/nmicrobiol.2017.104.
2
Clinical and Pathophysiological Overview of Acinetobacter Infections: a Century of Challenges.
Clin Microbiol Rev. 2017 Jan;30(1):409-447. doi: 10.1128/CMR.00058-16.
3
New insights into the regulatory pathways associated with the activation of the stringent response in bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.
J Antimicrob Chemother. 2016 Oct;71(10):2810-4. doi: 10.1093/jac/dkw230. Epub 2016 Jun 20.
4
β-Lactams and β-Lactamase Inhibitors: An Overview.
Cold Spring Harb Perspect Med. 2016 Aug 1;6(8):a025247. doi: 10.1101/cshperspect.a025247.
5
New β-Lactamase Inhibitors in the Clinic.
Infect Dis Clin North Am. 2016 Jun;30(2):441-464. doi: 10.1016/j.idc.2016.02.007.
6
Interactions of OP0595, a Novel Triple-Action Diazabicyclooctane, with β-Lactams against OP0595-Resistant Enterobacteriaceae Mutants.
Antimicrob Agents Chemother. 2015 Nov 9;60(1):554-60. doi: 10.1128/AAC.02184-15. Print 2016 Jan.
7
Contribution of Acinetobacter-derived cephalosporinase-30 to sulbactam resistance in Acinetobacter baumannii.
Front Microbiol. 2015 Mar 25;6:231. doi: 10.3389/fmicb.2015.00231. eCollection 2015.
8
OP0595, a new diazabicyclooctane: mode of action as a serine β-lactamase inhibitor, antibiotic and β-lactam 'enhancer'.
J Antimicrob Chemother. 2015 Oct;70(10):2779-86. doi: 10.1093/jac/dkv166. Epub 2015 Jun 18.
9
Emerging broad-spectrum resistance in Pseudomonas aeruginosa and Acinetobacter baumannii: Mechanisms and epidemiology.
Int J Antimicrob Agents. 2015 Jun;45(6):568-85. doi: 10.1016/j.ijantimicag.2015.03.001. Epub 2015 Mar 24.
10
Amdinocillin (Mecillinam) resistance mutations in clinical isolates and laboratory-selected mutants of Escherichia coli.
Antimicrob Agents Chemother. 2015 Mar;59(3):1718-27. doi: 10.1128/AAC.04819-14. Epub 2015 Jan 12.
Zotero 插件